CD53 and neoplasm: The combined effects of molecular-targeted drugs (including antibodies) and ADCs synergistically involve multiple mechanisms, such as improving intratumoral drug delivery by targeting tumor blood vessels, regulating tumor cell surface antigen expression, overcoming intratumoral heterogeneity and tumor drug resistance, and synthetic lethality.